肿瘤负荷与初治晚期非小细胞肺癌程序性细胞死亡-1/程序性细胞死亡配体-1抑制剂疗效的关联
研究连续纳入260例初治晚期非小细胞肺癌患者,分免疫检查点抑制剂单药、铂类双药化疗、免疫联合化疗三队列。免疫单药队列中低肿瘤负荷者无进展生存期显著长于高肿瘤负荷者,中位17.9 vs 4.3个月,加权风险比0.32。高肿瘤负荷与免疫抑制表型相关,导致免疫治疗疗效差,作者认为需开发联合或新策略。
要点
- 免疫单药队列中低肿瘤负荷者无进展生存期显著优于高肿瘤负荷者,中位17.9 vs 4.3个月,加权风险比0.32(95%CI 0.19-0.53)。
- 化疗队列和免疫联合化疗队列中未见肿瘤负荷与疗效的类似差异。
- 免疫相关基因表达谱分析提示高肿瘤负荷通过M2型巨噬细胞、血管生成、转化生长因子-β及促肿瘤信号通路介导免疫抵抗。
核心结论
- 高肿瘤负荷与晚期非小细胞肺癌免疫检查点抑制剂治疗的不良结局相关,其机制涉及免疫抑制表型。
- 作者认为针对此类疾病开发联合或新型治疗策略是必要的。
研究设计与样本
- 连续纳入260例初治晚期非小细胞肺癌患者,分为免疫检查点抑制剂单药队列、铂类双药化疗队列和免疫联合铂类双药化疗队列。
- 肿瘤负荷基于实体瘤疗效评价标准可测量靶病灶直径之和估算。
- 免疫单药队列的无进展生存期按肿瘤负荷分析为预设主要终点,采用倾向评分加权生存曲线和限制性平均生存时间分析。
- 化疗队列作为对照以判断肿瘤负荷是否预测免疫治疗结局,免疫联合化疗队列为探索性分析。
- 通过治疗前肿瘤组织的免疫相关基因表达谱分析评估肿瘤负荷与肿瘤免疫状态的关系。
主要发现
- 免疫单药队列中,低肿瘤负荷患者无进展生存期显著长于高肿瘤负荷患者,中位17.9 vs 4.3个月,加权风险比0.32(95%CI 0.19-0.53)。
- 化疗队列和免疫联合化疗队列中未见肿瘤负荷与无进展生存期的类似差异。
- 总生存期的显著差异也仅在免疫单药队列中观察到。
- 基于限制性平均生存时间的分析证实了上述结果。
- 免疫相关基因表达谱分析提示高肿瘤负荷相关的免疫抵抗涉及M2型巨噬细胞、血管生成、转化生长因子-β及促肿瘤信号通路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour burden (TB) is implicated in resistance to programmed cell death-1/PD-L1 inhibitor (immune checkpoint inhibitor [ICI]) therapy. However, whether TB contributes to such resistance in non-small-cell lung cancer (NSCLC) has remained unknown. METHODS: A total of 260 treatment-naïve patients with advanced NSCLC who started ICI monotherapy (ICI cohort), platinum-doublet therapy (Chemo cohort) or ICI and platinum-doublet therapy (ICI+Chemo cohort) as first-line treatment were consecutively included. TB was estimated on the basis of the sum of the diameters of measurable target lesions as per Response Evaluation Criteria in Solid Tumours. Progression-free survival (PFS) in the ICI cohort was evaluated as per TB as a preplanned primary objective, with the analysis based on propensity score-weighted survival curves and estimation of restricted mean survival time (RMST). The Chemo cohort served as a control to determine whether TB is predictive of ICI treatment outcomes. The ICI+Chemo cohort was exploratory. The relation of TB to tumour immune status was assessed by immune-related gene expression profiling (irGEP) of pretreatment tumour tissue. RESULTS: In the ICI cohort, patients with a low TB showed a significantly longer PFS than did those with a high TB (median, 17.9 vs 4.3 months; weighted hazard ratio, 0.32 [95% confidence interval, 0.19-0.53]). No such difference was apparent in the other cohorts. A significant difference in overall survival was also observed only in the ICI cohort. RMST-based analysis confirmed these results. The irGEP analysis implicated M2-type macrophages, angiogenesis and transforming growth factor-β as well as protumourigenic signalling pathways in ICI resistance conferred by a high TB. CONCLUSION: A high TB was associated with a poor outcome of ICI therapy for advanced NSCLC as a result of immunosuppressive phenotypes. Development of combination or novel treatment strategies for such disease is thus warranted.
引用
- Suzuki S, Haratani K, Hayashi H, et al. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. Eur J Cancer. 2021. PMID: 34922263. doi:10.1016/j.ejca.2021.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。